Praluent® (alirocumab) – Expanded indication
March 11, 2024 - Regeneron announced the FDA approval of Praluent (alirocumab), as an adjunct to diet and other low density lipoprotein cholesterol (LDL-C)-lowering therapies in pediatric patients aged 8 years and older with heterozygous familial.
Download PDF
